STING1 and neoplasm: Activation of the STING pathway can also potently enhance antitumor immunity, underscored by preclinical studies in which the murine STING agonist DMXAA or the cross-species STING agonist ADU-S100 have been demonstrated to suppress tumor progression and increase survival in an adaptive immune cell-dependent manner12–17.